Depression with insomnia: a still-uncertain signal for magnetic stimulation

Seven trials in patients with depression and insomnia symptoms

The review includes 709 participants: 367 in groups receiving repetitive transcranial magnetic stimulation and 342 in control groups. All trials used high-frequency stimulation targeting the left dorsolateral prefrontal cortex.

The researchers assessed sleep quality and depressive symptoms. The available abstract specifies neither the exact nature of the control interventions nor the duration of treatment and follow-up. This missing information is needed to assess the conditions under which the results were obtained and whether they persisted over time.

An average improvement, not a guarantee of better sleep

For sleep quality, the analysis reports a standardized mean difference of 0.97 in favor of stimulation, with a 95% confidence interval ranging from 0.23 to 1.71. This measure allows results expressed on different scales to be compared. It does not correspond to a number of extra minutes of sleep and does not indicate the probability that a patient will experience an improvement.

Depressive symptoms also appear to improve, with a standardized mean difference of 0.61 and a confidence interval of 0.38 to 0.84. However, the reduction in time taken to fall asleep is not statistically conclusive. The favorable signal for overall sleep quality therefore does not mean that patients fall asleep faster.

Results vary widely between studies

The main caveat is the high heterogeneity of results on the Pittsburgh Sleep Quality Index: I² reaches 91%. The trials therefore do not provide a consistent estimate of the benefit.

According to the subgroup analyses reported in the abstract, differences in stimulation frequency and baseline antidepressant use could contribute to this variability. This is not enough to identify optimal settings or determine which patients would benefit most from treatment.

The authors rate the certainty of the evidence as low to very low and consider their findings exploratory. This caveat limits the practical implications of the average improvement observed.

Tolerability still needs cautious interpretation

The analysis finds no statistically significant difference in adverse reactions: the relative risk is 1.09, with a confidence interval of 0.80 to 1.48. This lack of a detected difference demonstrates neither equivalent safety nor an absence of risk.

The abstract does not detail the reported events, contraindications or excluded populations. Nor does it establish whether the improvement in sleep is independent of the improvement in depression. These results are therefore not enough to turn magnetic stimulation into a general recommendation for insomnia.

What we can take away

The signal is favorable for sleep quality in patients with depression who have insomnia symptoms. But the variability of the results and the low certainty of the evidence prevent any general recommendation or protocol from being drawn.